Synchronous tunable wavelength spacing dual-wavelength SOA fiber ring laser using Fiber Bragg grating pair in a hybrid tuning package

A Dual-Wavelength Semiconductor Optical Amplifier (DW-SOA) based fiber ring laser with synchronous wavelength tunability is proposed and experimentally demonstrated. The SOA gain medium strongly suppresses mode competition, thus allowing stable dual-wavelength laser oscillation. The wavelength spacing of the two lasers can be tuned synchronously using a modified hybrid-tuning package incorporating a pair of Fiber Bragg Gratings (FBGs). The DW-SOA demonstrates a laser output with a wavelength spacing of between 0.10 and 8.30 nm (wavelength shift inequality of 0.08 to 0.75 nm). The relationship between the applied strain and wavelength shift of the two tuning modes is also analyze

The holographic superconductors in higher-dimensional AdS soliton

We explore the behaviors of the holographic superconductors at zero temperature for a charged scalar field coupled to a Maxwell field in higher-dimensional AdS soliton spacetime via analytical way. In the probe limit, we obtain the critical chemical potentials increase linearly as a total dimension $d$ grows up. We find that the critical exponent for condensation operator is obtained as 1/2 independently of $d$, and the charge density is linearly related to the chemical potential near the critical point. Furthermore, we consider a slightly generalized setup the Einstein-Power-Maxwell field theory, and find that the critical exponent for condensation operator is given as $1/(4-2n)$ in terms of a power parameter $n$ of the Power-Maxwell field, and the charge density is proportional to the chemical potential to the power of $1/(2-n)$.Comment: LaTeX, 16 pages, 5 figures, typos corrected, one reference added, version to appear in European Physical Journal

Higher Dimensional Charged Rotating Dilaton Black Holes

In this paper, we present the metric for the $n$-dimensional charged slowly rotating dilaton black hole with $N = [(n -1)/2]$ independent rotation parameters, associated with $N$ orthogonal planes of rotation in the background of asymptotically flat and asymptotically (anti)-de Sitter spacetime. The mass, angular momentum and the gyromagnetic ratio of such a black hole are determined for the arbitrary values of the dilaton coupling constant. We find that the gyromagnetic ratio crucially depends on the dilaton coupling constant, $\alpha$, and decreases with increasing $\alpha$ in any dimension.Comment: 15 pages, 1 figur

Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model

10.1007/s11373-006-9082-xJournal of Biomedical Science134579-59

Serum magnesium and calcium levels in relation to ischemic stroke : Mendelian randomization study

ObjectiveTo determine whether serum magnesium and calcium concentrations are causally associated with ischemic stroke or any of its subtypes using the mendelian randomization approach.MethodsAnalyses were conducted using summary statistics data for 13 single-nucleotide polymorphisms robustly associated with serum magnesium (n = 6) or serum calcium (n = 7) concentrations. The corresponding data for ischemic stroke were obtained from the MEGASTROKE consortium (34,217 cases and 404,630 noncases).ResultsIn standard mendelian randomization analysis, the odds ratios for each 0.1 mmol/L (about 1 SD) increase in genetically predicted serum magnesium concentrations were 0.78 (95% confidence interval [CI] 0.69-0.89; p = 1.3 7 10-4) for all ischemic stroke, 0.63 (95% CI 0.50-0.80; p = 1.6 7 10-4) for cardioembolic stroke, and 0.60 (95% CI 0.44-0.82; p = 0.001) for large artery stroke; there was no association with small vessel stroke (odds ratio 0.90, 95% CI 0.67-1.20; p = 0.46). Only the association with cardioembolic stroke was robust in sensitivity analyses. There was no association of genetically predicted serum calcium concentrations with all ischemic stroke (per 0.5 mg/dL [about 1 SD] increase in serum calcium: odds ratio 1.03, 95% CI 0.88-1.21) or with any subtype.ConclusionsThis study found that genetically higher serum magnesium concentrations are associated with a reduced risk of cardioembolic stroke but found no significant association of genetically higher serum calcium concentrations with any ischemic stroke subtype

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation